Biotx AI, a German biotech informatics company with a global reach, leverages large-scale genome-wide association study (GWAS) and phenotypic data to inform drug target identification and repositioning. Their platform applies Mendelian randomization and machine learning techniques to discern disease causality and predict optimal drug targets and patient subpopulations. Biotx AI has entered collaborations to apply this technology, including with Heartbeat Bio on heart failure treatments, demonstrating increased efficiency and risk reduction in drug development pipelines.